Master bibliography — type 2 diabetes¶

Last audited: 2026-08-30. Every PMID below was retrieved or re-resolved through live PubMed E-utilities during this audit session.

Core evidence¶

ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008. PMID 18539917 — tags: [type-2-diabetes] — cited by: complications.md, glycemic-management-and-legacy-trials.md, red-flags-and-safety-concerns.md
ADA Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care-2026. Diabetes Care. 2026. PMID 41358899 — tags: [type-2-diabetes] — cited by: complications.md, guidelines.md, overview.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
ADA Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care-2026. Diabetes Care. 2026. PMID 41358893 — tags: [type-2-diabetes] — cited by: biomarkers.md, guidelines.md, overview.md, prevention.md, red-flags-and-safety-concerns.md
ADA Professional Practice Committee. Retinopathy, Neuropathy, and Foot Care-2026. Diabetes Care. 2026. PMID 41358886 — tags: [type-2-diabetes] — cited by: complications.md, guidelines.md, overview.md, red-flags-and-safety-concerns.md, youth-onset-t2d.md
ADA Professional Practice Committee. Summary of Revisions: Standards of Care-2026. Diabetes Care. 2026. PMID 41358896 — tags: [type-2-diabetes] — cited by: guidelines.md
Adler AI, et al. UKPDS 91: 24-year post-trial monitoring. Lancet. 2024;404:145-155. PMID 38772405 — tags: [type-2-diabetes] — cited by: biomarkers.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, overview.md, pathophysiology-and-subtypes.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes. N Engl J Med. 2008. PMID 18539916 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md
Afroz A, et al. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries. BMC Health Serv Res. 2018;18:972. PMID 30558591 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md
Agarwal A, et al. Living guideline for T2D therapeutics. BMJ. 2025. PMID 40813129 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, sglt2-inhibitors-and-kidney-heart.md
Ahlqvist E, et al. Novel subgroups of adult-onset diabetes. Lancet Diabetes Endocrinol. 2018;6:361-369. PMID 29503172 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md
Ahmad A, et al. Precision prognostics for cardiovascular disease in T2D. Commun Med. 2024;4:11. PMID 38253823 — tags: [type-2-diabetes] — cited by: biomarkers.md
Al-Mrabeh A. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? Cardiovasc Endocrinol Metab. 2020;9:132-142. PMID 33225228 — tags: [type-2-diabetes] — cited by: pathophysiology-and-subtypes.md
American Diabetes Association Professional Practice Committee. Pharmacologic Approaches: Standards of Care-2026. Diabetes Care. 2026. PMID 41358900 — tags: [type-2-diabetes] — cited by: complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, youth-onset-t2d.md
Andersson T, et al. Mortality trends and cause of death in patients with new-onset type 2 diabetes and controls. Diabetes Res Clin Pract. 2018;138:81-89. PMID 29421310 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Aronne LJ, et al. Tirzepatide Compared with Semaglutide for Obesity. N Engl J Med. 2025. PMID 40353578 — tags: [type-2-diabetes] — cited by: incretin-therapies.md, metabolic-surgery.md, overview.md
Arslanian S, et al. β-cell function and glycemic failure in TODAY. Pediatr Diabetes. 2020;21:575-585. PMID 32064729 — tags: [type-2-diabetes] — cited by: youth-onset-t2d.md
Cai K, et al. Retinopathy in newly diagnosed T2D. Diabetes Metab Res Rev. 2023;39:e3586. PMID 36286346 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md
Cannon CP, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020. PMID 32966714 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, sglt2-inhibitors-and-kidney-heart.md
Carrasco-Zanini J, et al. Multi-omic prediction of incident T2D. Diabetologia. 2024;67:102-112. PMID 37889320 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md
Chew NWS, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023;35:414-428.e3. PMID 36889281 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Chopra S, et al. Effective primary care management of T2D for indigenous populations. PLoS One. 2022;17:e0276396. PMID 36355789 — tags: [type-2-diabetes] — cited by: patient-experience-and-advocacy.md
Courcoulas AP, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery. JAMA. 2024;331:654-664. PMID 38411644 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, metabolic-surgery.md, remission-and-weight-management.md
Cummings DE, Rubino F. Metabolic surgery for treatment of type 2 diabetes. Diabetologia. 2018;61:257-264. PMID 29224190 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md, remission-and-weight-management.md
Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. Diabetes Care. 2022. PMID 36148880 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md, guidelines.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
DeFronzo RA. Current issues in the treatment of type 2 diabetes. Am J Med. 2010;123:S38-S48. PMID 20206731 — tags: [type-2-diabetes] — cited by: pathophysiology-and-subtypes.md
Dennis JM, et al. Disease progression and treatment response in T2D subgroups. Lancet Diabetes Endocrinol. 2019;7:442-451. PMID 31047901 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md
Deutsch AJ, et al. Phenotypic and genetic classification of diabetes. Diabetologia. 2022;65:1758-1769. PMID 35953726 — tags: [type-2-diabetes] — cited by: pathophysiology-and-subtypes.md
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the DPP Outcomes Study. Lancet Diabetes Endocrinol. 2015. PMID 26377054 — tags: [type-2-diabetes] — cited by: biomarkers.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, youth-onset-t2d.md
Driessen S, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82:487-503. PMID 38147315 — tags: [type-2-diabetes] — cited by: complications.md
Duckworth W, et al. Glucose control and vascular complications in veterans. N Engl J Med. 2009. PMID 19092145 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md
Dutta S, et al. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors. J Family Med Prim Care. 2022;11:927-940. PMID 35495849 — tags: [type-2-diabetes] — cited by: red-flags-and-safety-concerns.md
Einarson TR, et al. Economic Burden of Cardiovascular Disease in Type 2 Diabetes. Value Health. 2018;21:881-890. PMID 30005761 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. PMID 36331190 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
Frías JP, et al. Tirzepatide versus Semaglutide. N Engl J Med. 2021. PMID 34170647 — tags: [type-2-diabetes] — cited by: biomarkers.md, clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, incretin-therapies.md, metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes. Lancet. 2023. PMID 37385275 — tags: [type-2-diabetes] — cited by: incretin-therapies.md, metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
GBD 2019 Diabetes and Air Pollution Collaborators. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2.5 air pollution, 1990-2019. Lancet Planet Health. 2022;6:e586-e600. PMID 35809588 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, prevention.md
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. Lancet. 2023;402:203-234. PMID 37356446 — tags: [type-2-diabetes] — cited by: biomarkers.md, complications.md, epidemiology-and-burden.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes. Lancet. 2019;394:121-130. PMID 31189511 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, sglt2-inhibitors-and-kidney-heart.md
González-González JG, et al. Values, preferences and burden of treatment for GLP-1RA and SGLT2 initiation. BMJ Open. 2021;11:e049130. PMID 34244276 — tags: [type-2-diabetes] — cited by: patient-experience-and-advocacy.md, youth-onset-t2d.md
GRADE Study Research Group. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022;387:1075-1088. PMID 36129997 — tags: [type-2-diabetes] — cited by: biomarkers.md, overview.md, pathophysiology-and-subtypes.md
Nathan DM, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022;387:1063-1074. PMID 36129996 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md, overview.md
Gyawali B, et al. Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014. Glob Health Action. 2015;8:29088. PMID 26613684 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Hall V, et al. Diabetes in Sub Saharan Africa 1999-2011. BMC Public Health. 2011;11:564. PMID 21756350 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
He Q, et al. Global Burden of type 2 diabetes in non-elderly individuals 1990 to 2021 and projections for 2050. Diabetes Metab. 2025;51:101660. PMID 40348179 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. PMID 32970396 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). Lancet. 2018;392:1519-1529. PMID 30291013 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Holman RR, et al. 10-year follow-up of intensive glucose control. N Engl J Med. 2008;359:1577-1589. PMID 18784090 — tags: [type-2-diabetes] — cited by: complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, overview.md
Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes. N Engl J Med. 2017. PMID 28910237 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Huang Q, et al. Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, with forecasts to 2050. Front Endocrinol. 2025;16:1538143. PMID 40895618 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes. N Engl J Med. 2019. PMID 31185157 — tags: [type-2-diabetes] — cited by: incretin-therapies.md, overview.md
Jastreboff AM, et al. Tirzepatide for Obesity. N Engl J Med. 2022. PMID 35658024 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, incretin-therapies.md, metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md
Kautzky-Willer A, et al. Sex differences in type 2 diabetes. Diabetologia. 2023;66:986-1002. PMID 36897358 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, prevention.md
Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. PMID 11832527 — tags: [type-2-diabetes] — cited by: biomarkers.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, youth-onset-t2d.md
Kristensen SL, et al. GLP-1RA cardiovascular, mortality, and kidney outcomes. Lancet Diabetes Endocrinol. 2019;7:776-785. PMID 31422062 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, complications.md, incretin-therapies.md, metabolic-surgery.md, sglt2-inhibitors-and-kidney-heart.md
Lean MEJ, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. Lancet Diabetes Endocrinol. 2019. PMID 30852132 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md
Lean MEJ, et al. Five-year follow-up of DiRECT. Lancet Diabetes Endocrinol. 2024. PMID 38423026 — tags: [type-2-diabetes] — cited by: biomarkers.md, glycemic-management-and-legacy-trials.md, guidelines.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md, youth-onset-t2d.md
Lean MEJ, et al. Primary care-led weight management for remission. Lancet. 2018. PMID 29221645 — tags: [type-2-diabetes] — cited by: biomarkers.md, glycemic-management-and-legacy-trials.md, guidelines.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, youth-onset-t2d.md
Lincoff AM, et al. Semaglutide CV Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, incretin-therapies.md, metabolic-surgery.md, overview.md, prevention.md
Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care. 2022. PMID 35312758 — tags: [type-2-diabetes] — cited by: overview.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md
Ma X, et al. Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050. Front Endocrinol. 2025;16:1513008. PMID 40060381 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md
Magliano DJ, et al. Trends in the incidence of young-adult-onset diabetes by diabetes type. Lancet Diabetes Endocrinol. 2024;12:915-923. PMID 39541997 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, youth-onset-t2d.md
Mann JFE, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017. PMID 28854085 — tags: [type-2-diabetes] — cited by: incretin-therapies.md, overview.md
Marso SP, et al. Liraglutide Cardiovascular Outcomes. N Engl J Med. 2016. PMID 27295427 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
Marso SP, et al. Semaglutide Cardiovascular Outcomes. N Engl J Med. 2016. PMID 27633186 — tags: [type-2-diabetes] — cited by: biomarkers.md, clinical-trials-landscape.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008. PMID 31535829 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, complications.md, sglt2-inhibitors-and-kidney-heart.md
Mingrone G, et al. Metabolic surgery versus conventional medical therapy: 10-year follow-up. Lancet. 2021;397:293-304. PMID 33485454 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, metabolic-surgery.md, remission-and-weight-management.md
Nanayakkara N, et al. Age at T2D diagnosis and vascular complications. Diabetologia. 2021;64:275-287. PMID 33313987 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md, patient-experience-and-advocacy.md, prevention.md, youth-onset-t2d.md
Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017. PMID 28605608 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
O'Hearn M, et al. Incident type 2 diabetes attributable to suboptimal diet in 184 countries. Nat Med. 2023;29:982-995. PMID 37069363 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, prevention.md
Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-1424. PMID 32865377 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, complications.md, sglt2-inhibitors-and-kidney-heart.md
Palmer SC, et al. SGLT2 inhibitors and GLP-1RA network meta-analysis. BMJ. 2021. PMID 33441402 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md
Perkovic V, et al. Canagliflozin Renal Outcomes. N Engl J Med. 2019. PMID 30990260 — tags: [type-2-diabetes] — cited by: biomarkers.md, clinical-trials-landscape.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
Perkovic V, et al. Semaglutide on CKD. N Engl J Med. 2024. PMID 38785209 — tags: [type-2-diabetes] — cited by: biomarkers.md, clinical-trials-landscape.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71:816-824. PMID 28422124 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Qi QYD, et al. Ten-year outcomes of gastric band surgery in overweight people with T2D. Diabetes Obes Metab. 2023;25:1464-1472. PMID 36700392 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md
Ramos-Levi AM, et al. Statistical models to predict T2D remission after bariatric surgery. J Diabetes. 2014;6:472-477. PMID 24433454 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md
Rawshani A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017. PMID 28402770 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md, overview.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
Riddle MC, et al. Definition and Interpretation of Remission. Diabetes Care. 2021. PMID 34462270 — tags: [type-2-diabetes] — cited by: biomarkers.md, complications.md, incretin-therapies.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md
Sattar N, et al. Tirzepatide cardiovascular event risk assessment. Nat Med. 2022;28:591-598. PMID 35210595 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes: 5-Year Outcomes. N Engl J Med. 2017. PMID 28199805 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, incretin-therapies.md, metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md
Seuring T, et al. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33:811-831. PMID 25787932 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, metabolic-surgery.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md
Shah AS, et al. Arterial stiffness and cardiac structure in young adults with youth-onset T2D. J Am Soc Echocardiogr. 2022;35:620-628.e4. PMID 35149207 — tags: [type-2-diabetes] — cited by: youth-onset-t2d.md
Sheng B, et al. Long-Term Effects of Bariatric Surgery on T2D Outcomes. Obes Surg. 2017;27:2724-2732. PMID 28801703 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md
Speight J, et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 2024. PMID 38128969 — tags: [type-2-diabetes] — cited by: biomarkers.md, guidelines.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, prevention.md, remission-and-weight-management.md, youth-onset-t2d.md
Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. PMID 34879977 — tags: [type-2-diabetes] — cited by: biomarkers.md, epidemiology-and-burden.md, guidelines.md, incretin-therapies.md, metabolic-surgery.md, overview.md, patient-experience-and-advocacy.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
Suzuki K, et al. Genetic drivers of heterogeneity in T2D pathophysiology. Nature. 2024;627:347-357. PMID 38374256 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md
Syn NL, et al. Metabolic-bariatric surgery and long-term survival. Lancet. 2021;397:1830-1841. PMID 33965067 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md, remission-and-weight-management.md
Taylor R. Calorie restriction and reversal of type 2 diabetes. Expert Rev Endocrinol Metab. 2016. PMID 30058916 — tags: [type-2-diabetes] — cited by: biomarkers.md, metabolic-surgery.md, overview.md, pathophysiology-and-subtypes.md, prevention.md, remission-and-weight-management.md
Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. J Intern Med. 2021;289:754-770. PMID 33289165 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md, prevention.md, remission-and-weight-management.md
Taylor R. Understanding the cause of type 2 diabetes. Lancet Diabetes Endocrinol. 2024;12:664-673. PMID 39038473 — tags: [type-2-diabetes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md, remission-and-weight-management.md
Teo ZL, et al. Global prevalence of diabetic retinopathy. Ophthalmology. 2021;128:1580-1591. PMID 33940045 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md
Tobias DK, et al. Precision diabetes medicine consensus. Nat Med. 2023. PMID 37794253 — tags: [type-2-diabetes] — cited by: biomarkers.md, overview.md, pathophysiology-and-subtypes.md
TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012. PMID 22540912 — tags: [type-2-diabetes] — cited by: complications.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, youth-onset-t2d.md
TODAY Study Group. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021. PMID 34320286 — tags: [type-2-diabetes] — cited by: biomarkers.md, complications.md, guidelines.md, overview.md, pathophysiology-and-subtypes.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, remission-and-weight-management.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md
TODAY Study Group. Longitudinal Changes in Cardiac Structure and Function. Circ Heart Fail. 2020;13:e006685. PMID 32498621 — tags: [type-2-diabetes] — cited by: youth-onset-t2d.md
TODAY Study Group. Postintervention effects on glycemic failure and β-cell function. Diabetes Care. 2021;44:75-80. PMID 33290248 — tags: [type-2-diabetes] — cited by: youth-onset-t2d.md
UKPDS Group. Effect of intensive blood-glucose control with metformin (UKPDS 34). Lancet. 1998. PMID 9742977 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md, metabolic-surgery.md, overview.md
UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin (UKPDS 33). Lancet. 1998. PMID 9742976 — tags: [type-2-diabetes] — cited by: glycemic-management-and-legacy-trials.md, guidelines.md, overview.md
Uthman OA, et al. Global prevalence and trends in hypertension and type 2 diabetes mellitus among slum residents. BMJ Open. 2022;12:e052393. PMID 35210339 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Walders-Abramson N, et al. Stressful life events, adherence and psychosocial functioning in youth with T2D. J Pediatr. 2014;165:504-508.e1. PMID 24948348 — tags: [type-2-diabetes] — cited by: youth-onset-t2d.md
Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. PMID 15111519 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019. PMID 30415602 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md
Xie J, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019. BMJ. 2022;379:e072385. PMID 36740855 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md, prevention.md, youth-onset-t2d.md
Ye J, et al. Cellular mechanism of diabetes remission by bariatric surgery. Trends Endocrinol Metab. 2023;34:590-600. PMID 37574405 — tags: [type-2-diabetes] — cited by: metabolic-surgery.md, remission-and-weight-management.md
Yu HJ, et al. Incidence and temporal trends in type 2 diabetes by weight status. J Glob Health. 2023;13:04088. PMID 37651631 — tags: [type-2-diabetes] — cited by: epidemiology-and-burden.md
Zhang H, et al. Global burden of metabolic diseases, 1990-2021. Metabolism. 2024;160:155999. PMID 39151887 — tags: [type-2-diabetes] — cited by: complications.md, epidemiology-and-burden.md
Zinman B, et al. Empagliflozin Cardiovascular Outcomes. N Engl J Med. 2015. PMID 26378978 — tags: [type-2-diabetes] — cited by: clinical-trials-landscape.md, complications.md, glycemic-management-and-legacy-trials.md, guidelines.md, incretin-therapies.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, sglt2-inhibitors-and-kidney-heart.md, youth-onset-t2d.md

Deepening pass — 2026-08-30¶

Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50. PMID 11333990 — tags: [prevention] — cited by: prevention.md
Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93. PMID 12556541 — tags: [complications, glycemic-management-and-legacy-trials, overview] — cited by: complications.md, glycemic-management-and-legacy-trials.md, overview.md
Sjöström L, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-93. PMID 15616203 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Ramachandran A, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-97. PMID 16391903 — tags: [prevention] — cited by: prevention.md
Lindström J, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-9. PMID 17098085 — tags: [prevention] — cited by: prevention.md
Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. PMID 18256393 — tags: [complications, glycemic-management-and-legacy-trials, overview] — cited by: complications.md, glycemic-management-and-legacy-trials.md, overview.md
Li G, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783-9. PMID 18502303 — tags: [prevention] — cited by: prevention.md
Ratner RE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93:4774-9. PMID 18826999 — tags: [prevention] — cited by: prevention.md
Defronzo RA, et al. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95. PMID 19336687 — tags: [overview, pathophysiology-and-subtypes] — cited by: overview.md, pathophysiology-and-subtypes.md
Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-21. PMID 19515410 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Snehalatha C, et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care. 2009;32:1796-801. PMID 19587369 — tags: [prevention] — cited by: prevention.md
Knowler WC, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-86. PMID 19878986 — tags: [prevention] — cited by: prevention.md
Ramachandran A, et al. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). Diabetes Care. 2010;33:2164-8. PMID 20519663 — tags: [prevention] — cited by: prevention.md
Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-44. PMID 20587587 — tags: [complications, glycemic-management-and-legacy-trials] — cited by: complications.md, glycemic-management-and-legacy-trials.md
Zoungas S, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-8. PMID 20925543 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Gong Q, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54:300-7. PMID 21046360 — tags: [prevention] — cited by: prevention.md
Lim EL, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506-14. PMID 21656330 — tags: [pathophysiology-and-subtypes, remission-and-weight-management] — cited by: pathophysiology-and-subtypes.md, remission-and-weight-management.md
Taylor R, et al. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med. 2013;30:267-75. PMID 23075228 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Sjöström L, et al. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-34. PMID 23163728 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Gregg EW, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489-96. PMID 23288372 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Jones AG, et al. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30:803-17. PMID 23413806 — tags: [biomarkers] — cited by: biomarkers.md
Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014;370:2002-13. PMID 24679060 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Halban PA, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99:1983-92. PMID 24712577 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Pasquel FJ, et al. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014;37:3124-31. PMID 25342831 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Alejandro EU, et al. Natural history of β-cell adaptation and failure in type 2 diabetes. Mol Aspects Med. 2015;42:19-41. PMID 25542976 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Jackson IL, et al. Medication adherence in type 2 diabetes patients in Nigeria. Diabetes Technol Ther. 2015;17:398-404. PMID 25749392 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Menke A, et al. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015;314:1021-9. PMID 26348752 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Sohal T, et al. Barriers and Facilitators for Type-2 Diabetes Management in South Asians: A Systematic Review. PLoS One. 2015;10:e0136202. PMID 26383535 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Tancredi M, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373:1720-32. PMID 26510021 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Brundisini F, et al. Type 2 diabetes patients' and providers' differing perspectives on medication nonadherence: a qualitative meta-synthesis. BMC Health Serv Res. 2015;15:516. PMID 26596271 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Pfeffer MA, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247-57. PMID 26630143 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Study group, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513-1530. PMID 27061677 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Study group, et al. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016;39:1089-100. PMID 27289122 — tags: [complications, glycemic-management-and-legacy-trials] — cited by: complications.md, glycemic-management-and-legacy-trials.md
Gæde P, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298-2307. PMID 27531506 — tags: [complications, glycemic-management-and-legacy-trials, overview] — cited by: complications.md, glycemic-management-and-legacy-trials.md, overview.md
Florez JC, et al. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017;60:800-807. PMID 28283684 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Zoungas S, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431-437. PMID 28365411 — tags: [glycemic-management-and-legacy-trials] — cited by: glycemic-management-and-legacy-trials.md
Fayfman M, et al. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017;101:587-606. PMID 28372715 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Hulman A, et al. Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. Diabetologia. 2017;60:1252-1260. PMID 28409212 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Crawford MR, et al. INCREASED BONE TURNOVER IN TYPE 2 DIABETES PATIENTS RANDOMIZED TO BARIATRIC SURGERY VERSUS MEDICAL THERAPY AT 5 YEARS. Endocr Pract. 2018;24:256-264. PMID 29144812 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Qaseem A, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018;168:569-576. PMID 29507945 — tags: [guidelines] — cited by: guidelines.md
Study group, et al. Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2018;41:1717-1725. PMID 29941500 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Laiteerapong N, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42:416-426. PMID 30104301 — tags: [glycemic-management-and-legacy-trials] — cited by: glycemic-management-and-legacy-trials.md
Muskiet MHA, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:859-869. PMID 30292589 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-39. PMID 30424892 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Al Sayah F, et al. Association of Depressive Symptoms and Diabetes Distress With Severe Hypoglycemia in Adults With Type 2 Diabetes. Can J Diabetes. 2019;43:316-321. PMID 30578165 — tags: [patient-experience-and-advocacy, red-flags-and-safety-concerns] — cited by: patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md
Toyama T, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:1237-1250. PMID 30697905 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Tamborlane WV, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019;381:637-646. PMID 31034184 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Perrin N, et al. Effectiveness of psychoeducational interventions for the treatment of diabetes-specific emotional distress and glycaemic control in people with type 2 diabetes: A systematic review and meta-analysis. Prim Care Diabetes. 2019;13:556-567. PMID 31040069 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Reaven PD, et al. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med. 2019;380:2215-2224. PMID 31167051 — tags: [glycemic-management-and-legacy-trials] — cited by: glycemic-management-and-legacy-trials.md
Meigs JB, et al. The Genetic Epidemiology of Type 2 Diabetes: Opportunities for Health Translation. Curr Diab Rep. 2019;19:62. PMID 31332628 — tags: [biomarkers] — cited by: biomarkers.md
Pasquel FJ, et al. Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study. Diabetes Care. 2020;43:349-357. PMID 31704689 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Al-Mrabeh A, et al. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. Cell Metab. 2020;31:233-249.e4. PMID 31866441 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Vujkovic M, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52:680-691. PMID 32541925 — tags: [biomarkers, pathophysiology-and-subtypes] — cited by: biomarkers.md, pathophysiology-and-subtypes.md
Winkley K, et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24:1-232. PMID 32568666 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Choi DW, et al. Effect of socioeconomic deprivation on outcomes of diabetes complications in patients with type 2 diabetes mellitus: a nationwide population-based cohort study of South Korea. BMJ Open Diabetes Res Care. 2020;8. PMID 32611580 — tags: [complications, epidemiology-and-burden] — cited by: complications.md, epidemiology-and-burden.md
Hannon TS, et al. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020;21:1437-1446. PMID 32985775 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384:129-139. PMID 33200891 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384:117-128. PMID 33200892 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Kaur G, et al. Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis. PLoS One. 2020;15:e0242415. PMID 33216783 — tags: [biomarkers] — cited by: biomarkers.md
Rooney MR, et al. Risk of Progression to Diabetes Among Older Adults With Prediabetes. JAMA Intern Med. 2021;181:511-519. PMID 33555311 — tags: [prevention] — cited by: prevention.md
He Q, et al. Prescription drug coverage satisfaction, cost-reducing behavior, and medication nonadherence among Medicare beneficiaries with type 2 diabetes. J Manag Care Spec Pharm. 2021;27:696-705. PMID 34057396 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Chen J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021;53:840-860. PMID 34059833 — tags: [biomarkers] — cited by: biomarkers.md
Martens T, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021;325:2262-2272. PMID 34077499 — tags: [glycemic-management-and-legacy-trials] — cited by: glycemic-management-and-legacy-trials.md
Sam S, et al. Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021;44:1938-1947. PMID 34131048 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143-155. PMID 34186022 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385:896-907. PMID 34215025 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Xing L, et al. Clinical Characteristics and Risk of Diabetic Complications in Data-Driven Clusters Among Type 2 Diabetes. Front Endocrinol (Lausanne). 2021;12:617628. PMID 34276555 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Lawrence JM, et al. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA. 2021;326:717-727. PMID 34427600 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451-1461. PMID 34449189 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Lam CSP, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2022;145:565-574. PMID 34775781 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Churuangsuk C, et al. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65:14-36. PMID 34796367 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Saad RK, et al. Fracture risk following bariatric surgery: a systematic review and meta-analysis. Osteoporos Int. 2022;33:511-526. PMID 34988627 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Oyedeji AD, et al. Effectiveness of non-specialist delivered psychological interventions on glycemic control and mental health problems in individuals with type 2 diabetes: a systematic review and meta-analysis. Int J Ment Health Syst. 2022;16:9. PMID 35120528 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Shaka H, et al. Hospitalizations and inpatient mortality for hyperosmolar hyperglycemic state over a decade. Diabetes Res Clin Pract. 2022;185:109230. PMID 35122906 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Dahl D, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327:534-545. PMID 35133415 — tags: [incretin-therapies] — cited by: incretin-therapies.md
Flood D, et al. The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults. Lancet Healthy Longev. 2021;2:e340-e351. PMID 35211689 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Salminen P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA Surg. 2022;157:656-666. PMID 35731535 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Filippatos G, et al. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Circulation. 2022;146:676-686. PMID 35762322 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Laakso M, et al. Genetics of Type 2 Diabetes: Past, Present, and Future. Nutrients. 2022;14. PMID 35956377 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28:923-1049. PMID 35963508 — tags: [guidelines] — cited by: guidelines.md
Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387:1089-1098. PMID 36027570 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Yammine K, et al. Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis. Foot Ankle Surg. 2022;28:1170-1176. PMID 36028441 — tags: [complications] — cited by: complications.md
Wang YW, et al. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (Baltimore). 2022;101:e30072. PMID 36042668 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Zhang Y, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol. 2022;21:232. PMID 36335326 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Inzucchi SE, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022;10:869-881. PMID 36372069 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Tönnies T, et al. Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2060: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2023;46:313-320. PMID 36580405 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Navaneethan SD, et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Ann Intern Med. 2023;176:381-387. PMID 36623286 — tags: [guidelines] — cited by: guidelines.md
Laffel LM, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11:169-181. PMID 36738751 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Duong KNC, et al. Comparison of diagnostic accuracy for diabetes diagnosis: A systematic review and network meta-analysis. Front Med (Lausanne). 2023;10:1016381. PMID 36760402 — tags: [biomarkers] — cited by: biomarkers.md
Wedekind LE, et al. The utility of a type 2 diabetes polygenic score in addition to clinical variables for prediction of type 2 diabetes incidence in birth, youth and adult cohorts in an Indigenous study population. Diabetologia. 2023;66:847-860. PMID 36862161 — tags: [biomarkers] — cited by: biomarkers.md
Wagenknecht LE, et al. Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based SEARCH for Diabetes in Youth study. Lancet Diabetes Endocrinol. 2023;11:242-250. PMID 36868256 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Jayedi A, et al. Effect of calorie restriction in comparison to usual diet or usual care on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2023;117:870-882. PMID 36972801 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Samson SL, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29:305-340. PMID 37150579 — tags: [guidelines] — cited by: guidelines.md
Carlsson LMS, et al. Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish Obese Subjects. Int J Obes (Lond). 2023;47:931-938. PMID 37438611 — tags: [metabolic-surgery] — cited by: metabolic-surgery.md
Sheils NE, et al. Real-World Prevalence of Type 2 Diabetes Remission in a U.S. Insured Population Using a Large Administrative Claims Database. Diabetes Spectr. 2023;36:211-218. PMID 37583561 — tags: [overview, remission-and-weight-management] — cited by: overview.md, remission-and-weight-management.md
Helgason H, et al. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. JAMA. 2023;330:725-735. PMID 37606673 — tags: [biomarkers] — cited by: biomarkers.md
Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043-4140. PMID 37622663 — tags: [guidelines] — cited by: guidelines.md
Dambha-Miller H, et al. Type 2 diabetes remission trajectories and variation in risk of diabetes complications: A population-based cohort study. PLoS One. 2023;18:e0290791. PMID 37643199 — tags: [overview, remission-and-weight-management] — cited by: overview.md, remission-and-weight-management.md
Hamilton K, et al. Which diabetes specific patient reported outcomes should be measured in routine care? A systematic review to inform a core outcome set for adults with Type 1 and 2 diabetes mellitus: The European Health Outcomes Observatory (H2O) programme. Patient Educ Couns. 2023;116:107933. PMID 37672919 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Wang W, et al. Data-driven subgroups of newly diagnosed type 2 diabetes and the relationship with cardiovascular diseases at genetic and clinical levels in Chinese adults. Diabetes Metab Syndr. 2023;17:102850. PMID 37683311 — tags: [pathophysiology-and-subtypes] — cited by: pathophysiology-and-subtypes.md
Misra S, et al. Current insights and emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11:768-782. PMID 37708901 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Nicholls SJ, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11. PMID 37758044 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Bush KJ, et al. Influence of neighborhood-level socioeconomic deprivation and individual socioeconomic position on risk of developing type 2 diabetes in older men: a longitudinal analysis in the British Regional Heart Study cohort. BMJ Open Diabetes Res Care. 2023;11. PMID 37907278 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. PMID 37908750 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Dietsche KB, et al. Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. J Clin Endocrinol Metab. 2024;109:1361-1370. PMID 37967247 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Gregg EW, et al. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia. 2024;67:459-469. PMID 38233592 — tags: [complications, remission-and-weight-management] — cited by: complications.md, remission-and-weight-management.md
Sridhar VS, et al. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clin J Am Soc Nephrol. 2024;19:557-564. PMID 38277468 — tags: [sglt2-inhibitors-and-kidney-heart] — cited by: sglt2-inhibitors-and-kidney-heart.md
Younossi ZM, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22:1999-2010.e8. PMID 38521116 — tags: [complications] — cited by: complications.md
Qaseem A, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024;177:658-666. PMID 38639546 — tags: [guidelines] — cited by: guidelines.md
Drake T, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2024;177:618-632. PMID 38639549 — tags: [clinical-trials-landscape, guidelines, overview] — cited by: clinical-trials-landscape.md, guidelines.md, overview.md
Carlsson LMS, et al. Mortality in relation to diabetes remission in Swedish Obese Subjects - a prospective cohort study. Int J Surg. 2024;110:6581-6590. PMID 38896851 — tags: [metabolic-surgery, remission-and-weight-management] — cited by: metabolic-surgery.md, remission-and-weight-management.md
Sun Y, et al. Predictors of post-healing recurrence in patients with diabetic foot ulcers: A systematic review and meta-analysis. J Tissue Viability. 2024;33:542-549. PMID 39004600 — tags: [complications] — cited by: complications.md
Umpierrez GE, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47:1257-1275. PMID 39052901 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Neuen BL, et al. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1781-1790. PMID 39210781 — tags: [clinical-trials-landscape, overview, sglt2-inhibitors-and-kidney-heart] — cited by: clinical-trials-landscape.md, overview.md, sglt2-inhibitors-and-kidney-heart.md
Jayedi A, et al. Efficacy of lifestyle weight loss interventions on regression to normoglycemia and progression to type 2 diabetes in individuals with prediabetes: a systematic review and pairwise and dose-response meta-analyses. Am J Clin Nutr. 2024;120:1043-1052. PMID 39222689 — tags: [prevention] — cited by: prevention.md
Hu H, et al. Effectiveness of Nurse-Led Psychological Interventions on Diabetes Distress, Depression, and Glycemic Control in Individuals With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Psychosoc Nurs Ment Health Serv. 2025;63:11-18. PMID 39508628 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Study group, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404:2077-2093. PMID 39549716 — tags: [epidemiology-and-burden, overview] — cited by: epidemiology-and-burden.md, overview.md
Martens TW, et al. A Randomized Controlled Trial Using Continuous Glucose Monitoring to Guide Food Choices and Diabetes Self-Care in People with Type 2 Diabetes not Taking Insulin. Diabetes Technol Ther. 2025;27:261-270. PMID 39757879 — tags: [glycemic-management-and-legacy-trials] — cited by: glycemic-management-and-legacy-trials.md
Chen X, et al. Global, regional, and national burdens of type 1 and type 2 diabetes mellitus in adolescents from 1990 to 2021, with forecasts to 2030: a systematic analysis of the global burden of disease study 2021. BMC Med. 2025;23:48. PMID 39876009 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Marx N, et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151:1639-1650. PMID 40156843 — tags: [clinical-trials-landscape, incretin-therapies] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Lee MMY, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025;48:846-859. PMID 40156846 — tags: [clinical-trials-landscape, incretin-therapies] — cited by: clinical-trials-landscape.md, incretin-therapies.md
McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392:2001-2012. PMID 40162642 — tags: [clinical-trials-landscape, incretin-therapies] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Heckman-Stoddard BM, et al. Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. Cancer Prev Res (Phila). 2025;18:401-411. PMID 40243198 — tags: [prevention] — cited by: prevention.md
Schleicher E, et al. Call for Standardization of C-Peptide Measurement. J Diabetes Sci Technol. 2025. PMID 40781799 — tags: [biomarkers] — cited by: biomarkers.md
Nong K, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039. PMID 40813122 — tags: [clinical-trials-landscape, overview] — cited by: clinical-trials-landscape.md, overview.md
Stafford LK, et al. Global, regional, and national cascades of diabetes care, 2000-23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study. Lancet Diabetes Endocrinol. 2025;13:924-934. PMID 40934935 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Bjornstad P, et al. Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO. Clin J Am Soc Nephrol. 2026;21:273-282. PMID 41314692 — tags: [youth-onset-t2d] — cited by: youth-onset-t2d.md
Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393:2409-2420. PMID 41406444 — tags: [clinical-trials-landscape, incretin-therapies] — cited by: clinical-trials-landscape.md, incretin-therapies.md
Zoungas S, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026;14:544-557. PMID 42114520 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Konkol J, et al. A systematic review and meta-analysis of the association between low socioeconomic status and all-cause mortality in patients with diabetes. Front Public Health. 2026;14:1841893. PMID 42433401 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: a meta-analysis. J Diabetes Investig. 2025;16:83-92. PMID 39569606 — tags: [incretin-therapies, red-flags-and-safety-concerns] — cited by: incretin-therapies.md, red-flags-and-safety-concerns.md
Shoung RS, et al. Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions. Sci Rep. 2025;15:18363. PMID 40419497 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Fadini GP, et al. Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study. Lancet Reg Health Eur. 2025;59:101499. PMID 41142657 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Bianchi C, et al. Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes? Diabetes Obes Metab. 2026;28:4474-4487. PMID 41852334 — tags: [remission-and-weight-management] — cited by: remission-and-weight-management.md
Wen J, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8:e70113. PMID 40988099 — tags: [incretin-therapies, red-flags-and-safety-concerns] — cited by: incretin-therapies.md, red-flags-and-safety-concerns.md
Benny O, et al. Dose-response analysis of tirzepatide and acute pancreatitis: an international systematic review and quantitative meta-analysis of randomised trials. Pancreatology. 2026;26:552-565. PMID 41927408 — tags: [incretin-therapies, red-flags-and-safety-concerns] — cited by: incretin-therapies.md, red-flags-and-safety-concerns.md
Joiner KL, et al. Promoting Stigma-Free Language in Type 2 Diabetes Care Among Primary Care Clinicians: Randomized Controlled Pilot Trial. JMIR Diabetes. 2026;11:e95805. PMID 42579884 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Casper J, et al. Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data. Nephrol Dial Transplant. 2026. PMID 42658186 — tags: [clinical-trials-landscape, incretin-therapies, sglt2-inhibitors-and-kidney-heart] — cited by: clinical-trials-landscape.md, incretin-therapies.md, sglt2-inhibitors-and-kidney-heart.md
Campbell C, et al. The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis. Surg Obes Relat Dis. 2026. PMID 42660781 — tags: [metabolic-surgery, remission-and-weight-management] — cited by: metabolic-surgery.md, remission-and-weight-management.md